HAEMONETICS CORP (HAE) earnings date, results and what the price requires
NYSE · SEC CIK 0000313143 · SEC filings checked Oct 16, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 27, 2026 | Aug 6, 2026 | $339.4M | $33.0M | $0.72 | Filing |
| Mar 28, 2026 | May 7, 2026 | $346.4M | $-117.4M | $-0.41 | Filing |
| Dec 27, 2025 | Feb 5, 2026 | $339.0M | $44.7M | $0.95 | Filing |
| Sep 27, 2025 | Nov 6, 2025 | $327.3M | $38.7M | $0.81 | Filing |
| Jun 28, 2025 | Aug 7, 2025 | $321.4M | $34.0M | $0.70 | Filing |
| Mar 29, 2025 | May 8, 2025 | $330.6M | $-109.5M | $1.17 | Filing |
| Dec 28, 2024 | Feb 6, 2025 | $348.5M | $37.5M | $0.74 | Filing |
| Sep 28, 2024 | Nov 7, 2024 | $345.5M | $33.8M | $0.66 | Filing |
What would HAEMONETICS CORP have to report for its valuation to change?
At $118.28, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 37.3% a year, to $10.11. On that path the next quarter needs diluted EPS near $1.11, against $0.81 in the quarter ended Sep 27, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 37.3% | 37.3% |
| EPS needed in final year | $10.11 | $10.11 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. HAE goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.